Avicanna (TSX: AVCN) Announces Receipt of the First Colombian USDA Organic Certification for its Hemp Cultivation and Registration of 15 Additional Genetics
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/
TORONTO, Oct. 18, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce that Santa Marta Golden Hemp S.A.S. ("SMGH"), a majority owned subsidiary of the Company, has obtained a United States Department of Agriculture ("USDA") National Organic Program ("NOP") certification from Control Union Certifications, for its hemp cultivar, and has obtained registration for an additional 15 genetic strains of cannabis.
USDA Organic Certification
Receipt of a NOP certification from the USDA for the cultivation of hemp (non-psychoactive cannabis) makes SMGH the first producer to receive this certification in Colombia. As a result, SMGH's organic cultivation practices are now validated by the USDA, which positions the Company to provide certified organic hemp derivatives for use in supplements and food products produced or shipped to the United States. The USDA protects consumers by allowing certified growers to use the USDA organic logo on products that are grown without the use of synthetic fertilizers, pesticides or herbicides. Any products intended for medical purposes coming from this organic cultivated hemp are outside of the scope of this certificate and cannot be commercialized as "organic".
Aras Azadian, the Company's Chief Executive Officer, stated, "Receiving the USDA NOP certification marks a significant milestone in our commitment to help set the highest quality standards in organic and sustainable cannabis cultivation, as we take another step forward towards becoming a global leader in the CBD industry. We expect this achievement to facilitate our growth strategy, which includes the expansion of both our plant-derived active pharmaceutical ingredients ("APIs") and bulk CBD formulations, as well as our branded lines of finished derma-cosmetics and phyto-therapeutic products into the U.S. and European markets where the USDA certification is a premium differentiator for those product categories that allow hemp to be certified as organic."
About Organic Cultivation
Dedicated to environmental preservation, SMGH will cultivate 100% sun-grown USDA certified organic hemp. Implementing Good Agricultural and Collection Practices and promoting a living soil system, SMGH's plants will grow healthy. The use of chemical pesticides and herbicides is harmful for the consumer, the plant, and mostly the environment. Plants grown under the pressure of conventional practices don't develop to produce their full potential of nutrients and benefits. Chemicals used in conventional agriculture are responsible for poisoning water sources, damaging the soil and diminishing its ability to sequester carbon dioxide which is a major cause for global warming. SMGH strives to maintain its soils free from synthetic compounds as a compromise to our planet.
Registration of Additional Genetics
On October 18, 2019, Avicanna received confirmation that SMGH has obtained registrations for 11 strains of psychoactive cannabis and 4 strains of non-psychoactive cannabis. Following such registration, SMGH has a total of 14 registered strains of psychoactive cannabis and 5 registered strains of non-psychoactive cannabis. SMGH, can commence production of products containing each strain of non-psychoactive cannabis that has been registered and, upon receipt of a quota with respect to each registered psychoactive strain, SMGH will be able to commence production of products containing each strain of its registered psychoactive cannabis strains. In addition, such registration enables SMGH to market seeds of such registered genetics and export propagation material (upon receipt of necessary approvals).
"Achieving this additional registration not only expands Avicanna's genetic bank for commercial purposes but also reflects our commitment to work with a wide range of varieties that provide a new range of cannabinoids for our research and development projects. This registration will also enhance our capacity to continue improving and stabilizing high performance genetics as part of our breeding program," said Avicanna's Chief Agricultural Officer, Lucas Nosiglia.
About Avicanna
Avicanna is an Ontario corporation focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products through its two main business segments, cultivation and research and development.
Avicanna's two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia are the base for Avicanna's cultivation activities. These two companies are licensed to cultivate and process cannabis for the production of cannabis extracts and purified cannabinoids including cannabidiol (CBD) and tetrahydrocannabinol (THC).
Avicanna's research and development business is primarily conducted out of Canada at its headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto. Avicanna's scientific team develops products, and Avicanna has also engaged the services of researchers at the Leslie Dan Faculty of Pharmacy at the University of Toronto for the purpose of optimizing and improving upon its products.
Avicanna's research and development and cultivation activities are focused on the development of its key products, including plant-derived cannabinoid pharmaceuticals, phyto-therapeutics, derma-cosmetics and Extracts (defined as plant-derived cannabinoid extracts and purified cannabinoids, including distillates and isolates), with a goal of eventually having these products manufactured and distributed through various markets.
Stay Connected
For more information about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email info@avicanna.com.
Cautionary Note Regarding Forward-Looking Information and Statements
Certain information in this press release contains forward-looking statements. Such statements include but are not limited to the ability of the Company to use its organic hemp in supplements and food products, the expectation that the receipt of the NOP certification will allow the Company to accelerate growth, that SMGH will cultivate 100% sun-grown USDA organic hemp and that SMGH will be able to commence production of its registered psychoactive strains of cannabis. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict, including the risk factors set out under the heading "Risk Factors" in the Company's long form final prospectus dated July 8, 2019. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements, unless and until required by securities laws applicable to the Company.
SOURCE Avicanna Inc.
Garamendi and Hartzler Introduce Bill to Protect Service Members from Chinese-Controlled Generic Pharmaceutical Industry
Washington, DC—Today, Congressman John Garamendi (D-CA), Chairman of the Readiness Subcommittee within the House Armed Services Committee, and Congresswoman Vicky Hartzler (R-MO), Ranking Member of the Tactical Air and Land Forces Subcommittee within the House Armed Services Committee, introduced the "Pharmaceutical Independence Long-Term Readiness Reform Act" (H.R. 4710).
The legislation requires the Department of Defense to identify the vulnerabilities faced by our country’s dependence on Chinese pharmaceuticals, and to only purchase American-made raw materials, medicines, and vaccines for the military.
“Right now, China has the ability to attack the United States without firing a single shot by poisoning our servicemembers’ medicines or cutting off their supply.” Garamendi said. “The Chinese government is the principal developer of generic prescriptions, which account for approximately 90 percent of pharmaceuticals. China’s chokehold on the global pharmaceutical market leaves our servicemembers and our nation vulnerable to attack. We need to reinvigorate the United States industrial base to produce generic medicines and antibiotics domestically. Doing so will create thousands of new middle-class jobs and make our country safer. I appreciate Congresswoman Hartzler’s partnership in our effort to resolve this issue.”
“Put simply, China having control over the production of our military’s medicine poses a grave national security threat. Not only does it open the possibility of them deliberately manipulating our servicemember’s medical regimens and causing physical harm, but the Chinese government’s lack of proper oversight and regulatory standards on prescription drugs is also deeply alarming to me. We need to ensure that our military’s medicine is American-made,” Hartzler said.
The full text of the "Pharmaceutical Independence Long-Term Readiness Reform Act" (H.R. 4710) can be viewed here.
Coaster Introduces the Venture 500 ALEX to Support Pediatric Cancer Research
First of Kind “Mobile Lemonade Stand” Will Be Available for Rental and Purchase
[SAN FRANCISCO, CA] Today, Coaster Cycles unveiled a new model – the Coaster Venture 500 ALEX - inspired by its partnership with Alex’s Lemonade Stand Foundation (ALSF). This new model will be a key part of Coaster’s support to ALSF, a featured community partner of the Company. The limited edition mobile lemonade stand will operate at select locations in the Bay Area with all proceeds benefiting the Foundation.
Coaster manufactures and operates eco-friendly mobility products that provide transportation, delivery, and branding services for a range of clients, including Fortune 500s, governments, universities, events, and retailers. Coaster will offer the Coaster Venture 500 ALEX for direct purchase with proceeds benefiting ALSF.
Proudly made in the USA, Coaster builds all of its vehicles at its 24,000 sq. ft. facility in Missoula, MT. The Venture series offers a leading solution for food and beverage companies such as Starbucks, Aramark, Constellation, Pepsi, and many more. The Venture – and all Coaster Cycles - can operate in the bike lane, does not require a driver’ license, and helps reduce congestion and pollution.
“In building a partnership with ALSF, the product and mission alignment, potential for high scale impact, and our personal passion for the cause made it a perfect fit.” said Ben Morris, Founder and CEO of Coaster.
Our hope is that in making the Coaster Venture 500 ALEX available for purchase, and eventually rental, it will become a staple of concessions at concerts, sporting events, universities, corporate campuses and beyond, all in support of the Foundation.”
“We welcome the opportunity to work closely with Coaster. Like ALSF, Coaster is committed to providing resources for finding the best research and better, less toxic treatments for children fighting cancer,” said Liz Scott, co-executive director of ALSF and Alex’s mom.
In addition, as a Featured Community Partner, Coaster will support ALSF through a variety of charitable integrated programs. The company will make a donation that will help fund impactful research and family resources ($20) for every Coaster sold, offer clients the opportunity to add a donation to ALSF at checkout, organize Coaster service days in support of ALSF, and raise awareness of ALSF activities and fundraising initiatives.
About Alex's Lemonade Stand Foundation (ALSF)
Alex's Lemonade Stand Foundation (ALSF) emerged from the front yard lemonade stand of 4-year-old Alexandra “Alex” Scott, who was fighting cancer and wanted to raise money to find cures for all children with cancer. Her spirit and determination inspired others to support her cause, and when she passed away at the age of 8, she had raised $1 million. Since then, the Foundation bearing her name has evolved into a national fundraising movement. Today, ALSF is one of the leading funders of pediatric cancer research in the U.S. and Canada raising more than $175 million so far, funding nearly 1,000 research projects and providing programs to families affected by childhood cancer. For more information, visit AlexsLemonade.org.
About Coaster Cycles
Coaster Cycles' mission is to inspire communities and brands to move, connect and deliver with the world around them. Coaster manufactures and operates eco-friendly mobility products that provide transportation, delivery, and branding services for a range of clients, including Fortune 500s, governments, universities, events, and retailers. Proudly made in the USA, Coaster manufactures in a 24,000 sq. ft. facility in Missoula, MT. The company also operates fleets in Boston, New York and San Francisco and activates ad campaigns nationally.
Take It Slow: How to Get Back into Working out after a Long Break
For healthy adults, working out at least 20 minutes a day is highly recommended. For those of us with busy schedules, exercise can become less of a priority or even nonexistent overtime. Getting back into a workout regimen, if done properly, is possible. Taking proper precautions will get you back into your workout routine.
Seek Professional Advice Prior to Starting Your Regimen
Before starting your workout regimen, seek a healthcare professional and get a proper evaluation. Understanding your initial health condition will help determine the routine you should follow and if there are any issues, the physician can remedy them before beginning.
Pace Yourself
Jumping back into your original workout regimen can be injurious. Muscle deterioration comes with taking breaks from exercising, so starting with low-intensity workouts and gradually increasing the intensity will give the best results. Also, be comfortable with the intensity you can handle initially. If you can only tolerate one or two days per week, that is okay. Feeling obligated to doing more than your body can handle is counterproductive to achieving your workout goals.
Use Proper Warm-Ups and Cool-Downs When Exercising
Before working out, warm ups are necessary to get your body ready for the regimen’s intensity. Stretching is a great way to warm up. It is also important to stretch when cooling down after a workout, which brings your heart rate back down to its original rest rate. Your body also experiences delayed onset muscle soreness (DOMS) if you haven’t worked out consistently. Incorporating stretching into warm-up and cool-down routines will eliminate some of this soreness.
Be Sure to Rest
Resting is just as important to muscle restoration as your workout regimen. When your body is tired or sore, take heed and refrain from putting further stress on your muscles. Be sure to get adequate sleep also; exercising burns lots of calories, causing fatigue. Going to sleep earlier or taking a nap after a workout will help rebuild muscles and relieve soreness. Also, try working in massages whenever possible. If you suffer any severe soreness or joint pain, seek necessary healthcare, including knee pain treatmentor physical therapy.Getting back into working out is great, when done safely. The goal of getting in shape should be to maintain your health, so practicing healthy habits like resting, proper pace, and getting professional health evaluations are key to coming back to your exercising routine. Use self-awareness and ease into regimens to reach you
ProMIS Neurosciences advances Alzheimer's disease program targeting neurotoxic forms of tau
Data show antibody candidates bind toxic forms of tau and inhibit its propagation in a cellular model
TORONTO and CAMBRIDGE, MA, Oct. 17, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, continues to further develop antibody candidates that have shown selectivity for the toxic forms of tau. New pre-clinical data show that these antibody candidates can block the spread of pathogenic tau aggregate formation in a cellular model. Continued advancement of ProMIS' dual approach for Alzheimer's disease, which also includes antibody PMN310 targeting the toxic oligomers of amyloid-beta, aligns with research indicating that both misfolded proteins play a major role in disease progression and represent highly validated targets for therapy.
ProMIS announced its tau program in May 2019 when it identified several novel antibody candidates that preferentially bind toxic forms of tau. Pre-clinical data now show that these candidates can block the formation of pathogenic tau aggregates in a cellular model. ProMIS leveraged its proprietary drug discovery and development platform to identify conformational epitopes on misfolded tau and generate, evaluate and advance tau antibody candidates, demonstrating the platform's capacity for producing high-quality antibody candidates rapidly and cost-effectively.
"The misfolded, toxic forms of tau and amyloid-beta are the two most validated targets in Alzheimer's therapy development," said Elliot Goldstein, MD, President and CEO of ProMIS Neurosciences. "While addressing Alzheimer's will require a multifactorial approach, selective targeting of misfolded, toxic forms of both tau and amyloid-beta remains one of the most promising therapeutic strategies for Alzheimer's disease. We will continue to strengthen our programs, offering the critical one-two punch needed for a disease-modifying therapy, while simultaneously seeking ways to leverage emerging biomarkers to improve the success and speed of future clinical development."
To learn more about the search for therapies for Alzheimer's, Parkinson's and other neurodegenerative diseases, listen to the podcast, Saving Minds, at iTunes or Spotify.
About ProMIS Neurosciences ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery platform is based on the use of two complementary thermodynamic, computational discovery engines – ProMIS and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE ProMIS Neurosciences Inc.
Is a Herpes Vaccine Finally Here? By Dr. Eddie Fatakhov MD
A vaccine for genital herpes has been in the works for close to 100 years. The majority of these prospective vaccines have failed, with some even making it to the human testing phase. Genital Herpes, or Herpes Simplex Virus-2 (HSV-2), is spread by vaginal, anal or oral sex, and is a more serious condition than common cold sores, or Herpes Simplex Virus-1 (HSV-1).
Genital herpes is common in the United States according to the Centers for Disease Control and Prevention that estimates more than 1 in 6 people aged 14 to 49 have genital herpes, with as many as 90% of these people not even knowing they have herpes due to lack of symptoms. The concerning issue with genital herpes is that the virus can be spread by people who have no symptoms and essentially, do not know they have it.
With so many sexually transmitted diseases (STDs) that seem to be common knowledge in this day and age, what is important to note about genital herpes is that there is no known cure. Medications are available to reduce viral outbreaks and lessen the likelihood of spreading the virus to a partner, but no medication to make it disappear. Carrying genital herpes also makes you 3 to 4 more times at risk for other viruses such as HIV. The open sores caused by the herpes virus provide an entryway for HIV to enter the body. Genital herpes is also a little “discriminatory” when it comes to gender and ethnicity. Twice as many women have the virus than men. Male-to-female transmission of herpes is easier than female-to-male transmission. Genital herpes is also more common among non-Hispanic blacks than non-Hispanic whites. The trended research shows that economic differences play a role in the spread of genital herpes.
While genital herpes is widespread, it is not the most common STD. Human papillomavirus (HPV) has the dubious distinction as the most common STD, but it now has a vaccine. Genital herpes comes in second place, making the development of a vaccine imperative. University of Pennsylvania scientists may be closer than ever. Their most recent published results show that immunization not only totally prevented genital herpes in mice and guinea pigs, but it very effectively kept the virus from retreating into nerve roots. The nerve roots are where the infection can hide and remain symptomless yet still transmitted. These mice and guinea pigs developed no clinical infection (with symptoms), and no subclinical infection that allows for spreading without symptoms. The next step is to get approval from the FDA to begin human trials.
To those who question the importance of such a vaccine, or find yourself saying “just protect yourself, use condoms, get tested, know your partners, etc.”, understand genital herpes can carry much bigger risks than the potential outbreak of occasional painful sores on your body. If the infection is passed to an infant (which can happen before, during, or after birth), it can cause severe disability or even death from complications such as meningitis. This fact alone greatly supports the need for vaccination.
Although this is exciting news in the medical field, we would still be quite some time away from a final product. Clinical trials could take 8 years or longer. The long-term vision would be teenagers receiving an HSV-2 Vaccine alongside the HPV vaccine, which is already protecting them from cervical, throat and mouth cancer. We have made it a reality that we will now see future populations with a significantly lower prevalence of HPV, resulting in less cancer. While HSV-2 is a virus with no cure, a vaccine that could prevent someone from ever getting it to begin with, while also potentially reducing HIV transmission rates. This would be ground-breaking for our future generations.
In Search of the Perfect Strain: Top Cultivator in California’s “Wine Country” of Weed Shares Generational Wisdom Behind One Family’s Decades-Long Pursuit of the Perfect Toke
Committed to purity and sustainability, Autumn Brands’ Head Grower talks sixth-generation Dutch farming techniques and the challenges of spearheading a “no-spray” operation
LOS ANGELES, California – (October 17th, 2019): Backed by decades of hard-won sustainable farming expertise, 50% woman-owned Autumn Brands stands out as a sixth-generation, family-run operation with a health-centered holistic focus and refreshingly artisanal approach. Running a large-scale cannabis operation presents a variety of challenges for any commercial grower. Every aspect of cultivation requires strategic precision, from selecting the hardiest strains to keeping up with increasing demand for product. In a notoriously competitive market, many sellers rely on harsh chemicals and pesticides to speed the growth process and ensure a strong final product. Under the watchful eye of Head Grower Johnny Brand, Autumn Brands far surpasses federal and state regulatory standards, offering powerfully potent strains of clean, pesticide-free cannabis from a name customers trust for quality and consistency.
“As no-spray cannabis farmers, we have few of the tools traditional growers use to battle things like mildew and mold,” explains Johnny Brand of Autumn Brands’ rigorous, hands-on approach. Once he establishes that a particular strain is not hypersensitive to the ravages of moisture, he tests 10 plants and observes their unique growth patterns through three distinct stages: first, he notes how easily clones take root and how quickly they grow. Next, Brand looks for plants that swell quickly, producing strong trichomes (the sticky resin glands responsible for their THC, CBD, and other cannabinoid content) and terpenes (which give each strain its unique flavor and aroma). Finally, post-harvest, the plants are dried, hand-trimmed, and lab-tested to verify THC and CBD levels, as well as other beneficial cannabinoids.
“The full process takes around 6 months, and I’m constantly searching for new strains to test and grow,” says Brand. Fortunately, several family-owned greenhouses give the company a unique edge: the freedom to grow and test product year-round in conjunction with the weather. “Indoor grows can operate year-round, regardless of the weather. Outdoor grows can only cultivate in warmer seasons,” he explains. “We’ve grown in the same greenhouses for more than 27 years, as hard-won knowledge from my grandpa and my dad passed down to me. My favorite part of our approach is the ability to work with the seasons; some plants change color and growth speed depending on the weather - which makes the testing process especially challenging - but it’s also what keeps me engaged in the process.”
Autumn Brands brings an uncompromising work ethic, informed by generations of family farming, to the task of producing hand-selected, sun-grown buds - each hang-dried, hand-trimmed, and cured to preserve maximum potency and full healing benefits. Overseeing every stage of their no-spray growth process, Johnny Brand and his expert team deliver sustainably sourced, farm-to-consumer cannabis to a blossoming health and wellness market. Visit www.AutumnBrands.com to learn more and discover their full selection of premium flower, pre-rolls, and pre-filled cartridges. Follow on Instagram @AutumnBrands for the latest product releases and updates.
About Autumn Brands:
Autumn Brands is a licensed California cannabis cultivator dedicated to the synergy of health and wellness. The Autumn Brands’ family farm started in Holland more than a century ago, and today, sixth-generation farmers apply the same expertise garnered in growing the world’s finest tulips to producing pure and potent strains of cannabis in sunny, coastal Santa Barbara County. Autumn Brands is proud to be 50 percent woman-owned, free of pesticides and other harmful chemicals. For more information, visit www.autumnbrands.com or email leighanne@anderson-pr.com.
Canopy Growth completes previously announced acquisition of Beckley Canopy Therapeutics
SMITHS FALLS, ON & LONDON, Oct. 15, 2019 /CNW/ - Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) ("Canopy Growth" or the "Company") has closed the previously announced acquisition of all outstanding shares in the global cannabinoid based research company Beckley Canopy Therapeutics (Beckley Canopy), including the joint commercial venture Spectrum Biomedical UK. These teams will now be integrated into the broader Spectrum Therapeutics organization to increase the breadth of the clinical research being pursued under the Spectrum banner and to combine continental European and United Kingdom commercial teams.
As a part of the acquisition, Canopy Growth's European management structure will evolve. Paul Steckler and Steven Wooding will assume the roles of Co-Managing Directors in charge of all European operations. Paul is a seasoned pharmaceutical executive with over 20 years' experience in commercial roles, having worked in both large and small pharmaceutical companies including Pfizer. Steve has held multiple positions within a 27-year career at Janssen, the Pharmaceutical arm of Johnson & Johnson. Most recently, he was head of Global Commercial Strategy and Market Access for Janssen.
"The acquisition comes at a time when commercial opportunities across Europe are ramping up," said Mark Zekulin, CEO, Canopy Growth. "Spectrum Biomedical has completed all necessary approvals to import cannabis into the UK market and is proud to facilitate patient access to safe cannabinoid-based medicines there. Consolidating our UK-based operations will allow Canopy to simultaneously improve its research and commercial capabilities across the continent."
Beckley Canopy was formed as a joint venture in January 2018 between Beckley Research & Innovations ("BRI") and Canopy Growth to research and develop clinically validated cannabis-based medicines, with a strong focus on intellectual property protection. The research platform combined European and North American-based leaders in cannabis research from BRI and Canopy Growth to create a strong and complementary UK-based European partnership. Since its inception, Beckley Canopy has made significant progress in its core research areas, added additional indications of interest, and worked closely and in a complementary fashion with the global Canopy research team.
Here's to Future (European) Growth.
About Canopy Growth Corporation Canopy Growth (TSX:WEED, NYSE:CGC) is a world-leading diversified cannabis, hemp and cannabis device company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms, as well as medical devices through Canopy Growth's subsidiary, Storz & Bickel GMbH & Co. KG. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time. Canopy Growth has operations in over a dozen countries across five continents.
Canopy Growth's medical division, Spectrum Therapeutics is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public's understanding of cannabis, and has devoted millions of dollars toward cutting edge, commercializable research and IP development. Spectrum Therapeutics sells a range of full-spectrum products using its colour-coded classification Spectrum system as well as single cannabinoid Dronabinol under the brand Bionorica Ethics.
Canopy Growth operates retail stores across Canada under its award-winning Tweed and Tokyo Smoke banners. Tweed is a globally recognized cannabis brand which has built a large and loyal following by focusing on quality products and meaningful customer relationships.
From our historic public listing on the Toronto Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. Canopy Growth has established partnerships with leading sector names including cannabis icons Snoop Dogg and Seth Rogen, breeding legends DNA Genetics and Green House Seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates eleven licensed cannabis production sites with over 4.7 million square feet of production capacity, including over one million square feet of GMP certified production space. For more information visit www.canopygrowth.com
Notice Regarding Forward Looking Statements This news release contains "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements include statements with respect to strategic acquisitions. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including the Company's ability to satisfy provincial sales contracts or provinces purchasing all cannabis allocated to them, and such risks contained in the Company's annual information form dated June 25, 2019 and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities laws.
SOURCE Canopy Growth Corporation
Canopy Growth Announces Sale of Stake in AusCann
The companies will continue to collaborate in the Australian market
SMITHS FALLS, ON, Oct. 15, 2019 /CNW/ - Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) ("Canopy Growth") has sold its 42,087,639 shares in Australian cannabis company AusCann Group Holdings (AusCann) via an off market block trade at $0.15 per share for gross proceeds of $6.3 million. The trade was facilitated by Canaccord Australia.
The sale represents Canopy Growth's total 13.2% interest in AusCann.
"Canopy Growth remains optimistic about the future of the Australian medical cannabis market and will continue to collaborate with the team at Auscann to support greater physician understanding and patient access to high quality cannabis products throughout Australia," said Mark Zekulin, CEO, Canopy Growth. "The decision to divest our position in AusCann, which we obtained three years ago in exchange for support provided, will allow us to sharpen our focus on our wholly-owned operations in the market, while continuing to collaborate with our partners at AusCann."
Dr. Marcel Bonn-Miller, Canopy Growth's Global Senior Director of Clinical Science, will continue to sit on the AusCann Board of Directors to facilitate future collaboration.
Here's to Future Growth.
About Canopy Growth Corporation Canopy Growth (TSX:WEED, NYSE:CGC) is a world-leading diversified cannabis, hemp and cannabis device company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms, as well as medical devices through Canopy Growth's subsidiary, Storz & Bickel GMbH & Co. KG. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time. Canopy Growth has operations in over a dozen countries across five continents.
Canopy Growth's medical division, Spectrum Therapeutics is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public's understanding of cannabis, and has devoted millions of dollars toward cutting edge, commercializable research and IP development. Spectrum Therapeutics sells a range of full-spectrum products using its colour-coded classification Spectrum system as well as single cannabinoid Dronabinol under the brand Bionorica Ethics.
Canopy Growth operates retail stores across Canada under its award-winning Tweed and Tokyo Smoke banners. Tweed is a globally recognized cannabis brand which has built a large and loyal following by focusing on quality products and meaningful customer relationships.
From our historic public listing on the Toronto Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. Canopy Growth has established partnerships with leading sector names including cannabis icons Snoop Dogg and Seth Rogen, breeding legends DNA Genetics and Green House Seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates eleven licensed cannabis production sites with over 4.7 million square feet of production capacity, including over one million square feet of GMP certified production space. For more information visit www.canopygrowth.com
Notice Regarding Forward Looking Statements This news release contains "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements include statements with respect to divesting shares. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including the Company's ability to satisfy provincial sales contracts or provinces purchasing all cannabis allocated to them, and such risks contained in the Company's annual information form dated June 25, 2019 and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities laws.
SOURCE Canopy Growth Corporation
Avicanna Commences Trading on the OTCQX Market in the United States
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/
TORONTO, Oct. 15, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of cannabinoid-based products, is pleased to announce that its common shares will commence trading today on the OTCQX® Best Market in the United States under the symbol "AVCNF".
The OTCQX Best Market provides added service, value and convenience to U.S. investors, brokers and institutions seeking to trade Avicanna shares. OTCQX is OTC Markets Group's premier market for established, investor-focused U.S. and international companies. To be eligible, companies must meet high financial standards, follow best practice corporate governance, demonstrate compliance with U.S. securities laws, be current in their disclosure, and have a professional third-party sponsor introduction.
"Trading on the OTCQX Market represents a significant step in Avicanna's capital markets strategy and journey to become an international leader in the biopharmaceutical industry. The achievement will allow us increased access to the U.S. capital markets and industry participants with extensive experience in evaluating pharmaceutical companies. Trading on OTCQX is also expected to provide a streamlined process for U.S. investors to transact in our securities and enhanced liquidity for all shareholders," stated Setu Purohit, President of Avicanna Inc.
About Avicanna
Avicanna is an Ontario corporation focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products through its two main business segments, cultivation and research and development.
Avicanna's two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia are the base for Avicanna's cultivation activities. These two companies are licensed to cultivate and process cannabis for the production of cannabis extracts and purified cannabinoids including cannabidiol (CBD) and tetrahydrocannabinol (THC).
Avicanna's research and development business is primarily conducted out of Canada at its headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto. Avicanna's scientific team develops products, and Avicanna has also engaged the services of researchers at the Leslie Dan Faculty of Pharmacy at the University of Toronto for the purpose of optimizing and improving upon its products.
Avicanna's research and development and cultivation activities are focused on the development of its key products, including plant-derived cannabinoid pharmaceuticals, phyto-therapeutics, derma-cosmetics and Extracts (defined as plant-derived cannabinoid extracts and purified cannabinoids, including distillates and isolates), with a goal of eventually having these products manufactured and distributed through various markets.
Stay Connected
For more information about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email info@avicanna.com.
Cautionary Note Regarding Forward-Looking Information and Statements
Certain information in this press release contains forward-looking statements. Such statements include but are not limited to the expected benefits from the commencement of trading on the OTCQX Market. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict, including the risk factors set out under the heading "Risk Factors" in the Company's long form final prospectus dated July 8, 2019. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements, unless and until required by securities laws applicable to the Company.
SOURCE Avicanna Inc.
TRAIN IT RIGHT NEWSLETTER
Sign Up and get a free 7 day Train it Right HIIT Program!
